As Australia looks back on National Pain Week, held from 26–31 July, attention remains focused on one of the country’s most significant and under-recognised health challenges.
Chronic Pain Australia says 5.4 million Australians, including adults and children, live with chronic pain, according to its 2026 National Pain Report. The organisation has previously cited a figure of 3.6 million Australians living with chronic pain. Either way, the scale is substantial, with persistent pain affecting far more than physical health. It can disrupt employment, relationships, financial security, mental wellbeing and everyday life.
Despite advances in pain management, many patients continue to experience inadequate relief. Others face the challenges associated with long-term use of conventional medicines, including opioids.
That has driven researchers to investigate entirely different approaches to pain management, including psychedelic compounds.
While psilocybin has attracted considerable attention for its potential applications in depression and other psychiatric conditions, an emerging body of research suggests that psychedelics could also have a role in chronic pain.
The important caveat is that the science remains early.
The question is no longer simply whether psychedelics can make pain feel less intense. Researchers are beginning to investigate whether they can alter the neural processes that allow pain to become chronic in the first place.
A Different Way to Think About Pain
Conventional pain medicines generally work by reducing inflammation, altering neurotransmission or interrupting the transmission of pain signals.
Psychedelics may operate differently.
Psilocybin is converted in the body to psilocin, which acts primarily on serotonin 5-HT2A receptors. These receptors are widely distributed throughout the brain and are involved in perception, cognition, mood and other aspects of brain function.
The compound has also been associated with changes in neuroplasticity — the brain’s ability to reorganise and form new connections.
That is potentially important in chronic pain.
Persistent pain is not always a straightforward reflection of ongoing tissue damage. In some chronic pain conditions, changes within the central nervous system can contribute to sensitisation, causing the nervous system to amplify or maintain pain signals after the original injury or disease process has changed.
This has led researchers to investigate whether psychedelic compounds could influence the neural circuits involved in persistent pain rather than simply suppressing the sensation.
There is also a psychological dimension.
Chronic pain frequently occurs alongside depression, anxiety, trauma, social isolation and pain catastrophising. These factors can interact with the perception and persistence of pain, creating a cycle that can be difficult to break.
A therapy capable of influencing both neurological and psychological processes could therefore have potential advantages over treatments that target pain intensity alone.
But that remains a hypothesis, not an established clinical fact.
The Human Evidence Is Still Early
The most comprehensive evidence to date suggests that there is a signal worth investigating, but not yet enough evidence to conclude that psilocybin is an effective treatment for chronic pain.
A systematic review published in Regional Anesthesia and Pain Medicine identified 28 studies examining psilocybin and chronic pain. The research covered dosing, different pain conditions and patient outcomes.
The findings were encouraging enough for the authors to conclude that psilocybin shows potential, but the limitations were substantial.
More than three-quarters of the included studies — 76.2% — were assessed as being of low or very low quality.
The authors therefore called for better-designed studies using standardised treatment protocols and stronger clinical methodology.
An earlier 2024 scoping review reached a similar conclusion. It identified only nine relevant studies, including case reports, observational research and a randomised controlled trial, covering conditions including phantom limb pain, cluster headaches, fibromyalgia, spinal cord injury, complex regional pain syndrome and lumbar radiculopathy. The researchers concluded that psychedelics may have potential, but that further randomised, double-blind, placebo-controlled trials are needed.
That distinction is important.
There is enough evidence to justify serious research into psychedelics and pain. There is not yet enough evidence to describe psilocybin as an established treatment for chronic pain.
What Animal Studies Are Revealing
Some of the most interesting recent developments have come from laboratory research.
In 2025, researchers reported in Nature Neuroscience that a single dose of psilocybin produced sustained reductions in pain-related behaviour in mouse models of chronic pain. The animals also showed improvements in anxiety- and depression-like behaviours.
The researchers found evidence that psilocybin influenced neural activity in circuits associated with pain, including the anterior cingulate cortex, a brain region strongly implicated in the emotional and cognitive dimensions of pain.
The findings helped support the idea that psychedelics could potentially affect the neural networks involved in chronic pain rather than acting solely as conventional analgesics.
But the results should not be confused with evidence of efficacy in humans.
They were generated in animal models, and translating those findings into clinical treatment is a major scientific step that has yet to be completed.
More recent research has also produced a more complicated picture.
In April 2026, researchers publishing in Communications Biology reported that a single dose of psilocybin produced sustained anti-nociceptive effects in mouse models of neuropathic pain. More significantly, the researchers found that psilocybin enhanced the analgesic effects of gabapentin, suggesting that psychedelics could potentially act as a “primer” for existing pain medicines rather than necessarily replacing them.
The result is particularly interesting because it points towards a possible future in which psychedelic compounds are integrated into existing pain-management strategies.
But again, this remains preclinical research.
And not all recent animal research has produced positive results.
A separate Nature Communications study published in January 2026 tested psilocybin across three mouse models of pain and found no evidence of an immediate or persistent analgesic effect from a single dose.
The conflicting findings are a useful reminder of where the field currently stands: promising enough to warrant further investigation, but far from settled.
Why the Brain May Matter More Than the Pain Signal
The emerging research raises a broader question about how chronic pain should be treated.
If chronic pain involves long-lasting changes in the brain and nervous system, then simply blocking pain signals may not address every mechanism maintaining the condition.
Psychedelics are particularly interesting because their effects extend beyond conventional analgesia.
Researchers are investigating whether psychedelic compounds can alter patterns of neural activity, promote plasticity and influence how the brain assigns meaning and emotional significance to painful experiences.
That does not necessarily mean psychedelics “reset” the brain.
It may be more accurate to think of them as potentially modulating or reorganising neural networks involved in persistent pain.
This distinction matters because chronic pain is heterogeneous. The mechanisms involved in fibromyalgia, neuropathic pain, migraine, complex regional pain syndrome and cancer-related pain are not identical.
A psychedelic treatment that proves useful for one condition may not necessarily work for another.
Australia Is Building the Research Infrastructure
Australia has become an increasingly important centre for psychedelic medicine research, although the country’s psychedelic clinical research has largely focused on mental health rather than chronic pain.
The Australian National University is contributing to the field through its ASSESS study, which examines the psychological, cognitive and physiological effects of psilocybin and MDMA. Researchers are using measures including psychological assessments, cognitive testing and EEG to investigate how these medicines affect the brain and human experience.
The work is not a chronic pain trial, and it should not be presented as one.
Its significance is that research into the mechanisms, safety and effects of psychedelic medicines can help build the broader scientific and clinical knowledge required for future applications.
Australia’s psychedelic research ecosystem also extends beyond ANU, with universities and specialist research organisations investigating psychedelic medicines, psychotherapy and neuroscience.
That infrastructure could become increasingly relevant if larger clinical studies begin examining chronic pain.
For now, however, the country’s role is primarily in building the scientific foundation rather than delivering psychedelic treatment for chronic pain.
Beyond the Mental Health Paradigm
The psychedelic medicine field has largely been defined by its potential applications in mental health.
Chronic pain could eventually broaden that picture.
The overlap between chronic pain and mental health is substantial. People living with persistent pain can experience depression, anxiety, trauma, sleep disruption and social isolation, while psychological distress can in turn influence how pain is experienced and managed.
That makes psychedelic-assisted therapy particularly interesting as a potential multidimensional intervention.
The objective would not necessarily be to replace physiotherapy, rehabilitation, psychological treatment or conventional medicines.
Instead, psychedelics could eventually become one component of a broader multidisciplinary approach.
The recent preclinical evidence involving gabapentin is particularly relevant to this possibility. If the findings can eventually be replicated in humans, psychedelic compounds might be investigated alongside existing treatments rather than positioned as alternatives to everything that came before them.
That is a much more realistic proposition than the idea of a single psychedelic dose replacing conventional pain medicine.
What Needs to Happen Next
The next stage of research is straightforward in principle, even if it will be difficult in practice.
Researchers need larger, well-controlled human trials that can establish whether the signals seen in early research translate into meaningful and sustained improvements in patients with chronic pain.
Those studies will need to determine which pain conditions are most responsive, which patients are most likely to benefit, what dosing protocols are appropriate and how psychedelic treatment should be combined with psychotherapy and existing pain-management strategies.
Long-term safety will also need to be established.
The quality of the existing evidence makes this particularly important. The 28-study systematic review found that most of the available research was low or very low quality, while earlier reviews have highlighted the small number of controlled clinical studies.
There is also a need to understand whether the therapeutic effects depend on the psychedelic experience itself, the psychological support surrounding treatment, biological effects on neural circuits, or some combination of all three.
Those questions remain unresolved.
A Potential New Frontier in Pain Medicine
The promise of psychedelics for chronic pain remains exactly that: a promise.
There is currently no basis for presenting psilocybin as an established treatment for chronic pain, and the evidence from human research remains limited. Recent animal studies have produced encouraging results, but they have also produced conflicting findings.
That uncertainty is not a reason to dismiss the field.
It is a reason to study it properly.
The most compelling possibility is not necessarily that psychedelics could become another class of painkillers. It is that they could eventually offer a different way of approaching chronic pain — one that targets some of the neurological and psychological processes that allow pain to persist.
For millions of Australians living with chronic pain, that distinction could prove significant.
The next breakthrough in pain medicine may not come from simply suppressing pain signals.
It may come from understanding — and potentially changing — the way the brain and nervous system learn to experience pain.
